Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nicotinamide Riboside Bioenergetics Study
NCT03151707Phase 4Terminated
- Sponsor
- McLean Hospital
- Start
- Oct 2017
- Primary completion
- Sep 2022
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial, sponsored by McLean Hospital. Primary endpoint: Change From Baseline to the End of Treatment in Brain NAD+/NADH Ratio at 15 days. Started Oct 2017; status: terminated.
Beyond the preview
Go deeper on NCT03151707.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03151707.